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showed p¼ 0.064 (arm*10% TILs increase) and p¼ 0.019 (arm*TILs binary variable
with 20% cutoff).
Conclusions: TILs are an independent prognostic factor for HER2þ early breast cancer
patients treated with adjuvant chemotherapy and trastuzumab. Integration of TILs in
prognostic algorithms can help refining risk stratification and guiding therapeutic de-
escalation.
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Background: Adjuvant HDCT for high-risk BC is not beneficial overall compared to
conventional chemotherapy at the cost of considerable toxicity. HDCT benefit, how-
ever, may be present in very high-risk patients (i.e.>9 involved ALN) and in triple neg-
ative (TN) BC patients, although long-term results are lacking for most initial studies.
We evaluated long-term outcome of a randomized phase 3 study, conducted from 1993
to 99.
Methods: Patients aged<56 years with early BC and4 involved ALN were random-
ized to either conventional chemotherapy or HDCT as adjuvant systemic treatment.
The conventional arm consisted of 5x fluorouracil, epirubicin and cyclophosphamide
(FEC) 3-weekly. In the HDCT arm, the 5th FEC was replaced by cyclophosphamide
6000mg/m2, thiotepa 480mg/m2, carboplatin 1600mg/m2 and supported with autolo-
gous HSCT (Rodenhuis, NEJM 2003).We collected 20-year follow-up data frommedi-
cal records, general practitioners, and the Netherlands Cancer Registry. Endpoints were
relapse free survival (RFS), overall survival (OS), BC specific survival (BCSS), and safety
based on intention to treat analyses.
Results: 885 patients (64% 4-9 ALN, 36%>9 ALN; 53% ERþ/HER2-, 23%HER2þ,
16% TN, 8% unknown) were randomized to FEC (n¼ 443) or HDCT (n¼ 442). The
table shows efficacy results of univariable Coxmodels. With 20 years median follow-
up, relapse or death occurred in 272 patients (61%) who received FEC vs in 257 (58%)
HDCT patients (HR 0.88; 95%CI 0.74-1.05). The effect of HDCT compared to FEC
was most pronounced in patients with>9 involved ALN and in TNBC patients. In 138
TNBC patients the 20-year OS estimate was 52% after HDCT vs 39% after FEC. Long-
term safety and BCSS will also be presented at the meeting.
Table: 187O
RFS HDCT FEC
N 20 yr (%) 95% CI 20 yr (%) 95% CI HR 95% CI p
All 885 42 37-47 38 33-43 0.88 0.74-1.05 0.15
4-9 ALN 568 43 38-50 44 38-50 1.00 0.81-1.25 0.97
>9 ALN 317 39 31-47 27 21-36 0.71 0.54-0.94 0.02
ERþ/HER2- 469 40 34-47 36 30-43 0.83 0.66-1.04 0.11
HER2þ 205 38 30-49 42 33-52 1.15 0.80-1.63 0.46
TN 138 51 40-65 34 24-48 0.66 0.42-1.03 0.07
OS HDCT FEC
N 20 yr (%) 95% CI 20 yr (%) 95% CI HR 95% CI p
All 885 45 41-50 41 37-46 0.89 0.74-1.06 0.18
4-9 ALN 568 46 40-52 48 42-54 1.01 0.81-1.27 0.91
>9 ALN 317 44 37-53 30 23-38 0.72 0.54-0.95 0.02
ERþ/HER2- 469 46 40-53 40 34-47 0.81 0.64-1.03 0.09
HER2þ 205 40 32-51 46 37-56 1.15 0.80-1.66 0.44
TN 138 52 41-65 39 29-52 0.71 0.45-1.12 0.14
Conclusions: Long-term follow-up confirms survival benefit of HDCT in BC patients
with>9 involved ALN and suggests benefit in TNBC patients.
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Background: The EORTCQLQ-BR23 was one of the first disease specific questionnaire
developed in 1996 to assess quality of life (QoL) in patients with breast cancer (BC).
However, since 1996, major changes in BC treatment have occurred, requiring updat-
ing of the EORTC BCmodule. This abstract presents the phase I-III study updating the
EORTCQLQ-BR23.
Methods: The update of the EORTCQLQ-BR23module followed standard EORTC
guidelines. QoL issues relevant for BC patients were generated in the phase I-II. Results
of an extensive literature systematic review found 83 potential relevant QoL issues.
After shortening the issues lists for overlapping, already existing in QLQ-C30 and QLQ
BR-23 and following by interviews with patients and health care providers, 15 relevant
issues were transformed into 27 items. The preliminary module of 27 items was pre-
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